HUMAN METAPNEUMOVIRUS (HMPV): SYMPTOMS, TREATMENT, PREVENTION AND LATEST UPDATES
Medically Reviewed by Dr. Sony Sherpa (MBBS)
Human metapneumovirus (HMPV), a member of the Pneumoviridae family, was first identified in the Netherlands in 2001. This virus has since been recognized as a significant cause of respiratory tract infections worldwide, particularly in at-risk populations such as children under five, older adults, and immunocompromised individuals. HMPV infections contribute to seasonal respiratory illness peaks, often resembling influenza or respiratory syncytial virus (RSV) in clinical presentation.
Current Global Situation
HMPV outbreaks have been reported globally, with a notable surge in recent years. Increased detection through molecular diagnostic testing has revealed significant prevalence, especially in pediatric and elderly populations. This surge underscores the virus's impact on public health systems, with some hospitals experiencing strain on resources due to rising admissions. Public health authorities are monitoring HMPV closely to mitigate its spread and develop effective preventive measures.
Types of HMPV
HMPV is classified into two main genotypes: A and B, each further divided into sublineages (A1, A2, B1, B2). These genetic differences do not significantly alter the clinical symptoms but may influence the virus’s transmissibility and regional distribution.
What Causes HMPV?
HMPV is caused by a single-stranded RNA virus that primarily targets the respiratory epithelium. Genetic studies suggest that HMPV evolved from zoonotic transmission, possibly from avian metapneumovirus, highlighting its ability to cross species barriers. Understanding its origins provides insights into preventing future zoonotic transmissions.
Transmission
HMPV spreads through respiratory droplets released when an infected person coughs or sneezes. Touching your face after touching contaminated surfaces can also get you infected. The virus is highly contagious both before and during the symptomatic phase, with individuals potentially spreading the virus for several days. Risk factors for infection include young or advanced age, chronic respiratory conditions like asthma or COPD, and weakened immune systems.
HMPV Symptoms
This respiratory virus affects people of all ages. After exposure, the human metapneumovirus incubation period is typically 3–6 days before symptoms appear. The typical progression of HMPV infection begins with mild upper respiratory symptoms, including a runny nose and cough. In some instances, the infection can progress to involve the lower respiratory tract, leading to conditions such as bronchitis and pneumonia.
Common Symptoms
Symptoms of HMPV often mimic those of other respiratory viruses and include:
- Runny nose
- Cough
- Sore throat
- Fever
- Wheezing
- Difficulty breathing (dyspnea)
- Shortness of breath
- Rash (less common)
Symptoms in Children vs. Adults
Human metapneumovirus in kids frequently causes more severe symptoms, such as bronchiolitis, high fever, and significant wheezing. Children under five are particularly susceptible to complications. Human metapneumovirus in adults may lead to milder symptoms like a persistent cough or exacerbations of preexisting respiratory conditions.
How Long Does HMPV Last?
So, how long are you contagious with human metapneumovirus? The symptoms of HMPV typically last between 7 to 10 days. However, more severe cases in young children, older adults, or immunocompromised individuals can extend to two weeks or longer, particularly if secondary infections develop.
Similarity to RSV
HMPV is closely related to respiratory syncytial virus (RSV), and both viruses cause similar symptoms, such as wheezing and difficulty breathing. Like RSV, HMPV can lead to severe respiratory illnesses in young children and the elderly. However, RSV tends to peak in winter, while HMPV may appear later in spring.
Human Metapneumovirus vs Covid-19
Though both HMPV and COVID-19 are respiratory viruses, their symptoms can overlap but differ in severity. COVID-19 often presents with systemic symptoms, such as loss of taste or smell and fatigue, alongside respiratory symptoms. HMPV rarely causes such systemic effects. COVID-19 also has a longer incubation period (2–14 days) and is generally more transmissible and associated with higher rates of severe disease, including complications like blood clotting and organ failure.
By understanding the differences in symptoms and progression, individuals can better identify and seek appropriate care for HMPV.
Complications
While HMPV usually causes mild to moderate respiratory symptoms, complications can occur. It is important to seek immediate medical attention if symptoms worsen or if any of the following complications occur:
- Secondary Lower Respiratory Infections:
HMPV can lead to conditions like bronchiolitis, bronchitis, or pneumonia, which may cause severe breathing difficulties and require hospitalization. - Asthma or COPD Flare-Ups:
Individuals with asthma or chronic obstructive pulmonary disease (COPD) may experience exacerbations, leading to increased shortness of breath, wheezing, and chest tightness. - Ear Infections (Otitis Media):
In some cases, HMPV can cause middle ear infections, particularly in young children, leading to ear pain, fever, and irritability.
Mortality Rate
The mortality rate associated with HMPV infections is typically low among healthy individuals. However, it can be significantly higher in high-risk populations, such as infants, the elderly, and individuals with underlying health conditions. Estimates suggest a case fatality rate of 5%–15% in hospitalized patients, particularly those with severe respiratory distress or secondary complications.
Complications During Pregnancy
HMPV infection during pregnancy can pose risks to both the mother and fetus. Studies indicate that pregnant women with HMPV may have a higher likelihood of preterm birth, low birth weight, and other adverse neonatal outcomes, particularly in developing countries. The virus may also exacerbate maternal respiratory symptoms, increasing the risk of hypoxia and hospitalization. Pregnant women with HMPV should be closely monitored to mitigate potential complications.
Diagnosis
Accurate diagnosis of HMPV involves a combination of clinical evaluation and laboratory tests. Common diagnostic methods include:
- Swab from Nose or Throat:
A swab is used to collect a sample from the nose or throat to test for HMPV. - Bronchoscopy and X-Ray:
For patients with severe respiratory symptoms, a bronchoscopy may be performed to directly observe the airways. A chest X-ray can help assess the extent of lung involvement, such as bronchitis or pneumonia. - Direct Detection of Viral Genome:
- Nucleic Acid Amplification Test (NAAT): This is a highly sensitive method used to detect the HMPV genome in respiratory samples.
- Immunofluorescence or Enzyme Immunoassay: These tests identify viral antigens in respiratory secretions, providing a rapid diagnostic option.
Treatment Options
While there is no specific antiviral treatment for HMPV, management focuses on alleviating symptoms and providing supportive care.
Over-the-Counter Medications
- Fever and Pain Relievers: Over-the-counter medications, such as ibuprofen and acetaminophen can help manage fever and discomfort..
- Saline Nasal Sprays: These can relieve nasal congestion and help with breathing difficulties.
Corticosteroids for Symptom Relief
Corticosteroids may be prescribed in certain cases to reduce inflammation within the airways, alleviating symptoms such as wheezing and difficulty breathing.
Antiviral Medications
Antiviral medications may be considered for severe HMPV infections, particularly in people with underlying health conditions or weakened immune systems. However, their effectiveness against HMPV is still under investigation.
Supportive Care
- Hydration: Keeping the body hydrated helps maintain normal function, especially when fever or respiratory distress is present.
- Rest: Adequate rest is crucial for recovery from any viral infection.
Oxygen Therapy and IV Fluids
Individuals experiencing difficulty breathing or signs of respiratory distress may require oxygen therapy to maintain adequate oxygen levels. Intravenous (IV) fluids can help maintain hydration and support overall health.
Role of Antibiotics
It is important to note that antibiotics are ineffective in treating viral infections, including HMPV. However, they may be prescribed by a healthcare professional if a secondary bacterial infection, such as pneumonia or an ear infection, arises.
Most patients recover within 1 to 2 weeks, though recovery may take longer in severe cases.
Prevention Strategies
Preventive measures include:
- Frequent handwashing
- Covering coughs and sneezes
- Avoiding close contact with sick individuals
- Staying home when symptomatic
- Wearing masks in crowded places
Vaccination efforts are ongoing, with several promising candidates under development.
Recent HMPV Outbreaks
Recent outbreaks have placed significant strain on healthcare systems, particularly in pediatric wards, due to increased hospitalizations for severe respiratory illnesses.
Post-pandemic social interactions, weakened immunity due to reduced viral exposure during COVID-19 lockdowns, and seasonal factors have likely contributed to the rise in HMPV cases. In China, seasonal peaks in late winter and early spring have been especially notable.
Latest News and Updates
Recent advancements in HMPV research are focused on improving detection, treatment options, and understanding of the virus. One of the notable developments is the broader use of molecular diagnostic tests, which have enhanced the ability to detect HMPV more rapidly and accurately.
These tests, such as nucleic acid amplification and immunoassays, provide quicker and more reliable results, enabling healthcare providers to identify the virus early and initiate appropriate care. This technology has been key in expanding the use of molecular diagnostics in both clinical and research settings.
Vaccine Development
While there is currently no approved vaccine for HMPV, significant progress is being made in vaccine development.
- Vaccine Trials for HMPV and RSV
A promising new trial is underway for a combined vaccine to prevent both respiratory syncytial virus (RSV) and HMPV. This dual vaccine approach could simplify prevention strategies, especially for vulnerable groups. This innovative trial aims to assess the efficacy and safety of a combined vaccine. - Research on HMPV Vaccine Candidates
Ongoing studies are investigating several potential vaccine candidates. Recent research has focused on understanding HMPV's mechanisms of immunity, exploring different types of vaccines, such as protein-based and mRNA-based platforms. One study recently highlighted the progress in designing vaccines that could provide long-term immunity to HMPV and similar viruses.
Emerging Treatments and Preventive Measures
Alongside vaccine research, scientists are exploring antiviral medications, which could be used in severe cases of HMPV. While no specific antiviral therapy has been approved yet, studies on potential antiviral agents are in progress.
The broader application of molecular diagnostics, coupled with advancements in antiviral research, holds promise for more effective treatments and vaccines against HMPV. This progress could significantly improve patient outcomes and lessen the impact of HMPV-related respiratory infections.
To search for the best Pulmonary and Respiratory Medicine healthcare providers in Germany, India, Malaysia, Spain, Thailand, Turkey, the UAE, the UK and The USA, please use the Mya Care Search engine
To search for the best healthcare providers worldwide, please use the Mya Care search engine.